Integra LifeSciences Holdings Co. (NASDAQ:IART) Holdings Raised by Duality Advisers LP

Duality Advisers LP boosted its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 32.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 29,432 shares of the life sciences company’s stock after purchasing an additional 7,252 shares during the quarter. Duality Advisers LP’s holdings in Integra LifeSciences were worth $1,282,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Signaturefd LLC boosted its position in Integra LifeSciences by 248.5% during the 4th quarter. Signaturefd LLC now owns 582 shares of the life sciences company’s stock valued at $25,000 after purchasing an additional 415 shares during the period. Gladius Capital Management LP acquired a new position in Integra LifeSciences during the 3rd quarter worth $47,000. Covestor Ltd boosted its position in Integra LifeSciences by 82.5% during the 3rd quarter. Covestor Ltd now owns 2,037 shares of the life sciences company’s stock worth $78,000 after acquiring an additional 921 shares during the period. International Assets Investment Management LLC acquired a new position in Integra LifeSciences during the 4th quarter worth $190,000. Finally, Empirical Asset Management LLC acquired a new position in Integra LifeSciences during the 4th quarter worth $212,000. Institutional investors and hedge funds own 84.78% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Citigroup upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 price target for the company in a research report on Wednesday, April 3rd. StockNews.com lowered Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Friday, April 5th. JMP Securities reduced their price target on Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating for the company in a research report on Thursday, February 29th. Finally, Truist Financial cut their price objective on Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating for the company in a report on Friday, March 1st. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $44.89.

Integra LifeSciences Trading Up 1.4 %

Shares of Integra LifeSciences stock opened at $29.38 on Wednesday. The business has a fifty day simple moving average of $36.28 and a 200-day simple moving average of $38.97. The firm has a market cap of $2.31 billion, a price-to-earnings ratio of 35.40, a price-to-earnings-growth ratio of 0.87 and a beta of 1.12. The company has a quick ratio of 2.18, a current ratio of 3.45 and a debt-to-equity ratio of 0.94. Integra LifeSciences Holdings Co. has a fifty-two week low of $27.85 and a fifty-two week high of $59.10.

Integra LifeSciences (NASDAQ:IART) last announced its earnings results on Wednesday, February 28th. The life sciences company reported $0.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.01). The company had revenue of $397.00 million for the quarter, compared to analyst estimates of $399.30 million. Integra LifeSciences had a return on equity of 15.19% and a net margin of 4.39%. The firm’s revenue for the quarter was down .3% on a year-over-year basis. During the same period last year, the firm earned $0.94 earnings per share. On average, equities analysts forecast that Integra LifeSciences Holdings Co. will post 3.19 EPS for the current fiscal year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.